Hikal P/E Ratio
Hikal P/E ratio. Hikal (HIKAL) P/E ratio is not applicable — EPS (TTM) ₹-3.96. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company reported a loss in the most recent quarter. P/E ratio is not meaningful for loss-making periods.
Current EPS: ₹-3.96
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | 1.17 | 14 | Profit |
| Jun 2026 | -0.60 | -7 | Loss |
| Sept 2025 | -2.83 | -35 | Loss |
| Mar 2025 | 4.07 | 50 | Profit |
| Jun 2025 | -1.82 | -22 | Loss |
| Dec 2025 | -0.48 | -6 | Loss |
| Sept 2024 | 1.48 | 18 | Profit |
| Mar 2024 | 2.76 | 34 | Profit |
Healthcare Peers with Valid P/E Ratios — HIKAL Comparison
Healthcare sector average P/E 56.2, median 32.5 — HIKAL excluded (negative EPS).
Sector Average PE
56.2
Sector Median PE
32.5
Lowest PE
2.04
Profitable Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Hikal share price screener.
- Examine HIKAL earnings report for recent quarterly revenue, profit and EPS trends.
- Also explore Hikal stock price data download to track price trends across different timeframes.